What Does Immunomedics Do?

Total employees104
HeadquartersMorris Plains
Founded1982

Immunomedics, Inc. was a clinical-stage biopharmaceutical company dedicated to the development of monoclonal antibody-based therapeutics for the targeted treatment of cancer. The company's primary focus was on antibody-drug conjugates (ADCs), a class of potent biopharmaceutical drugs designed as a targeted therapy for treating cancer. Immunomedics' leading product, Trodelvy (sacituzumab govitecan-hziy), received FDA approval for treating metastatic triple-negative breast cancer. In October 2020, Immunomedics was acquired by Gilead Sciences, integrating its innovative ADC platform and oncology pipeline into Gilead's portfolio.

Where Is Immunomedics's Headquarters?

HQ Function

The headquarters served as the central hub for research and development, corporate operations, and manufacturing of its antibody-drug conjugates.

Notable Features:

The facility housed state-of-the-art laboratories for biologic drug development, ADC conjugation, and analytical testing, along with capabilities for clinical-scale manufacturing.

Work Culture:

Immunomedics fostered a science-driven, innovative, and collaborative work environment. Employees were deeply committed to advancing cancer treatments, driven by a strong sense of purpose to improve patient outcomes.

HQ Significance:

The Morris Plains headquarters was critical to Immunomedics' success, enabling the discovery, development, and initial manufacturing of Trodelvy and other pipeline ADC candidates.

Values Reflected in HQ: The headquarters embodied Immunomedics' commitment to scientific excellence, innovation in oncology, and a patient-centric approach to drug development.

Location:

Prior to its acquisition, Immunomedics' core R&D and manufacturing operations were centered in the United States. The company managed a global clinical trial program for its oncology drug candidates, with sites across North America, Europe, and other key regions. With the advancement of Trodelvy, Immunomedics was actively building its commercial infrastructure to support a global launch, including establishing a European presence.

Street Address:

300 The American Road

City:

Morris Plains

State/Province:

New Jersey

Country:

USA

Where Else Does Immunomedics Operate Around the World?

Zug, Switzerland

Address: Immunomedics AG, Dammstrasse 19, 6300 Zug, Switzerland (Historical)

To manage European market access, commercialization efforts, medical affairs, and coordinate clinical development programs within the European region.

Buying Intent Signals for Immunomedics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Immunomedics? Meet the Executive Team

As of April 2025, Immunomedics' leadership includes:

Harout Semerjian - President and Chief Executive Officer (from May 2020)
Dr. Behzad Aghazadeh - Executive Chairman
Dr. Loretta M. Itri - Chief Medical Officer
Michael R. Tussey, III - Chief Financial Officer (from June 2020)
Dr. Morris Rosenberg - Chief Technology Officer

Who's Investing in Immunomedics?

Immunomedics has been backed by several prominent investors over the years, including:

venBio Partners (Significant Shareholder)
Various institutional investors (As a publicly traded company, NASDAQ: IMMU, major holders included firms like BlackRock, Vanguard, etc.)

What Leadership Changes Has Immunomedics Seen Recently?

Hire2
Exits2

In the period leading up to its acquisition by Gilead in October 2020, Immunomedics experienced several key leadership transitions. These changes occurred as the company was advancing its lead drug Trodelvy through late-stage clinical trials, regulatory approval, and preparing for commercial launch.

Departures

Usama Malik, Usama Malik departed from his roles as CFO and CBO.
Brendan Delaney, Brendan Delaney stepped down as Chief Commercial Officer following organizational changes.

New Appointments:

Harout Semerjian, Harout Semerjian, formerly Chief Commercial Officer, was promoted to President and CEO.
Michael R. Tussey, III, Michael R. Tussey, III was appointed permanent Chief Financial Officer after serving as Interim CFO.

What Technology (Tech Stack) Is Used byImmunomedics?

Discover the tools Immunomedics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Immunomedics Email Formats and Examples

Prior to its acquisition by Gilead, Immunomedics likely utilized common corporate email formats. The most probable format would combine elements of an employee's name with the company domain.

[first_initial][last]@immunomedics.com

Format

jdoe@immunomedics.com

Example

90%

Success rate

What's the Latest News About Immunomedics?

Gilead Sciences / Business WireSeptember 13, 2020

Immunomedics to be Acquired by Gilead Sciences for $21 Billion

Gilead Sciences announced a definitive agreement to acquire Immunomedics for $88.00 per share in cash, valuing the company at approximately $21 billion. The acquisition provided Gilead with Trodelvy, a first-in-class Trop-2 directed antibody-drug conjugate....more

Immunomedics Press Release / FDAApril 22, 2020

Immunomedics Receives FDA Accelerated Approval for Trodelvy™ (sacituzumab govitecan-hziy) in Metastatic Triple-Negative Breast Cancer

The U.S. Food and Drug Administration (FDA) granted accelerated approval to Trodelvy for adult patients with metastatic triple-negative breast cancer (mTNBC) who received at least two prior therapies for metastatic disease. This marked a major milestone for Immunomedics and patients with mTNBC....more

Immunomedics Press ReleaseJuly 6, 2020

Immunomedics Announces Positive Results from Phase 3 ASCENT Study of Trodelvy in Metastatic Triple-Negative Breast Cancer

Immunomedics reported that the confirmatory Phase 3 ASCENT study, evaluating Trodelvy in patients with mTNBC who had received at least two prior therapies, met its primary endpoint of progression-free survival and key secondary endpoints, including overall survival....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Immunomedics, are just a search away.